A press release from RepliCel today for its cell based hair regeneration product for the treatment of male and female pattern baldness or androgenetic alopecia.
Since RepliCel has confirmed that they will attend Dr. Mwamba’s @My_WHTC_Clinic_Repre IHRP Hair Conference in Vancouver, Apr 2017, I suspect all this will also be presented and discussed at the conference.
According to today’s press release, 5 year trial data confirms safety profile for RepliCel’s high-dose dermal sheath cup cells (DSCC) treatment for hair loss. No serious side effects were reported during the entire long term study that lasted over 60 months.
Results for the injection site biopsies will also be released in the next several weeks, just in time for IHRP Hair Conference in Vancouver.
Efficacy data collected for the 19 trial patients over a 2 year period confirms the following:
The seven top-tier responders in the trial saw >10% increase in hair density at six months post-injection… At 24 months, the average hair density increase for these same seven participants was 8.3% over baseline, and three of these seven trial participants maintained a >10% increase in density over baseline. The largest increase in hair density over baseline observed in this group was a 21% increase at 24 months.
The top 10 participants reported at least a 5% or greater increase in hair density at six months post-injection with an average increase of 11.8%. This group demonstrated a sustained response at 24 months which averaged a 4.2% increase over baseline hair density.
The entire press release can be found here